In a series of 10 patients, blinded readers interpreting prostate scans acquired with the company's QTscan system displayed equal or better sensitivity for detection of cancer compared with multiparametric 7-tesla MRI.

The company said that QT's technology, low-frequency transmitted ultrasound volography, demonstrated 85.7% sensitivity and 93.9% specificity, while multiparametric MRI had 65.3% sensitivity and 96.6% specificity. QT Imaging believes the results indicate that the technology has potential as a low-cost high-resolution modality for prostate cancer.

The study was performed in collaboration with the Center for Interventional Oncology at the National Cancer Institute and Johns Hopkins University.